Beam Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Beam Therapeutics Inc. (BEAM), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are BEAM insiders buying or selling?
In the last 12 months, Beam Therapeutics Inc. insiders reported 0 open-market purchases ($0) and 19 sales ($19.5M) — net selling of $19.5M. Since January 2021, Trabud has recorded 85 Form 4 filings for BEAM: 0 buys ($0) and 85 sells ($128.4M).
Source: SEC EDGAR Form 4
What stands out
- No Beam Therapeutics Inc. insider made an open-market purchase in the last 12 months; the 19 reported open-market sales totaled $19.5M.
Key Statistics (January 2021 – Oct 17, 2026)
Total Form 4 filings
85
SEC EDGAR
Insider filers
8
Insider buys (0)
$0
Insider sells (85)
$128.4M
Insider sentiment
Net sellingNet insider flow of $128.4M in net selling since January 2021, and $19.5M in net selling over the last 12 months.
Recent BEAM insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 17, 2026 | John M. Evans | CEO | Sale | 50.0K | $23.77 | $1.2M | SEC ↗ |
| Oct 2, 2026 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sale | 187 | $24.41 | $4.6K | SEC ↗ |
| Jul 29, 2026 | Amy Simon | Chief Medical Officer | Sale | 16.7K | $25.74 | $429.0K | SEC ↗ |
| Jul 2, 2026 | Amy Simon | Chief Medical Officer | Sale | 373 | $34.73 | $13.0K | SEC ↗ |
| Jul 1, 2026 | John M. Evans | CEO | Sale | 50.0K | $34.90 | $1.7M | SEC ↗ |
| Jun 29, 2026 | FMR LLC | Other, 10% Owner | Sale | 284.9K | $35.24 | $10.0M | SEC ↗ |
| Apr 6, 2026 | John M. Evans | CEO | Sale | 30.1K | $24.58 | $739.3K | SEC ↗ |
| Apr 6, 2026 | Amy Simon | Chief Medical Officer | Sale | 6.7K | $24.58 | $164.7K | SEC ↗ |
| Apr 6, 2026 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sale | 3.2K | $24.58 | $79.7K | SEC ↗ |
| Apr 6, 2026 | Christine Bellon | Chief Legal Officer | Sale | 6.0K | $24.58 | $146.4K | SEC ↗ |
| Apr 6, 2026 | Giuseppe Ciaramella | President | Sale | 11.8K | $24.58 | $290.3K | SEC ↗ |
| Apr 1, 2026 | John M. Evans | CEO | Sale | 50.0K | $22.57 | $1.1M | SEC ↗ |
| Feb 26, 2026 | Giuseppe Ciaramella | President | Sale | 35.0K | $32.00 | $1.1M | SEC ↗ |
| Feb 2, 2026 | John M. Evans | CEO | Sale | 50.0K | $28.87 | $1.4M | SEC ↗ |
| Jan 26, 2026 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sale | 6.2K | $35.00 | $216.9K | SEC ↗ |
| Jan 26, 2026 | Christine Bellon | Chief Legal Officer | Sale | 1.4K | $34.00 | $46.6K | SEC ↗ |
| Jan 21, 2026 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sale | 3.0K | $30.12 | $91.4K | SEC ↗ |
| Jan 20, 2026 | Christine Bellon | Chief Legal Officer | Sale | 18.6K | $34.61 | $644.8K | SEC ↗ |
| Oct 29, 2025 | FMR LLC | Other, 10% Owner | Sale | 459 | $26.68 | $12.2K | SEC ↗ |
| Oct 3, 2025 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sale | 467 | $24.53 | $11.5K | SEC ↗ |
| Oct 3, 2025 | Christine Bellon | Chief Legal Officer | Sale | 373 | $24.53 | $9.1K | SEC ↗ |
| Oct 3, 2025 | John M. Evans | CEO | Sale | 50.0K | $24.57 | $1.2M | SEC ↗ |
| Aug 1, 2025 | FMR LLC | Other, 10% Owner | Sale | 48.4K | $20.50 | $991.7K | SEC ↗ |
| Jul 3, 2025 | Amy Simon | Chief Medical Officer | Sale | 1.3K | $19.17 | $24.0K | SEC ↗ |
| Apr 4, 2025 | Christine Bellon | Chief Legal Officer | Sale | 5.7K | $18.35 | $104.1K | SEC ↗ |
Showing the 25 most recent of 85 Form 4 filings for Beam Therapeutics Inc..
Most active BEAM insiders
- John M. Evans23 filings
- Giuseppe Ciaramella15 filings
- Christine Bellon11 filings
- Amy Simon10 filings
- Bethany J Cavanagh9 filings
Ask anything about BEAM insider activity
Use Trabud's AI agent to query Beam Therapeutics Inc.'s Form 4 history in plain English — "Show me BEAM CEO purchases this year" or compare it against any other ticker.
Open the AI agentBEAM insider trading FAQ
Are Beam Therapeutics Inc. insiders buying or selling?
In the last 12 months, Beam Therapeutics Inc. insiders reported 0 open-market purchases ($0) and 19 sales ($19.5M) — net selling of $19.5M. Since January 2021, Trabud has recorded 85 Form 4 filings for BEAM: 0 buys ($0) and 85 sells ($128.4M). Over the full record that is net selling of $128.4M.
How many insiders trade BEAM stock?
8 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Beam Therapeutics Inc.. The most recent filing was accepted on Oct 17, 2026.
Where does Trabud get BEAM insider trading data?
All BEAM insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.